Search results
Improved lung function and quality of life
- The use of single inhaler triple therapy for COPD patients can result in lower rates of moderate or severe exacerbations of COPD as well as improved lung function and quality of life compared with dual therapy with LABA/LAMA or ICS/LABA.
www.ncbi.nlm.nih.gov/pmc/articles/PMC6628970/
People also ask
Does single-Inhaler triple therapy improve lung health?
Does single Inhaler triple therapy improve obstructive pulmonary disease (COPD) exacerbation rates?
Does triple therapy improve lung health?
Jan 25, 2022 · The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: A systematic review and meta-analysis of randomized controlled trials.
- 10.3390/life12020173
- 2022/02
- Life (Basel). 2022 Feb; 12(2): 173.
Jul 9, 2020 · These results show that therapy with once-daily FF/UMEC/VI single-inhaler triple therapy improves patient symptoms and HRQoL compared with dual treatment with FF/VI or UMEC/VI in patients with symptomatic COPD and at risk of exacerbations.
- Maggie Tabberer, C. Elaine Jones, Sally Kilbride, David M.G. Halpin, David A. Lomas, Steven Pascoe, ...
- 10.1007/s12325-020-01409-8
- 2020
- Adv Ther. 2020; 37(9): 3775-3790.
Nov 4, 2019 · Triple therapy, provided as multiple inhalers, has in pooled analyses been shown to improve lung function, health-related quality of life and exacerbations [3–7]. However, evidence suggests that triple therapy is often over prescribed in clinical practice and used in patients who are not frequent exacerbators [ 8 – 10 ].
- Sue Langham, Jen Lewis, Nick Pooley, Nina Embleton, Julia Langham, MeiLan K. Han, James D. Chalmers
- 10.1186/s12931-019-1213-9
- 2019
- Respir Res. 2019; 20: 242.
- Search Strategy
- Study Selection and Data Extraction
- Quality Score and risk-of-bias Assessment
- Data Synthesis and Statistical Analysis
This meta-analysis followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement . This study was prospectively registered in Prospero (CRD42020186726). We used the following search terms in the PubMed, MEDLINE (OvidSP), EMBASE and Cochrane Library databases to identify studies published up to ...
Data were independently extracted by two reviewers. Any difference in opinion about eligibility was resolved through consensus. We collected information from each randomized trial about study features (title, year, author, study design and duration of follow-up, etc.), participants (mean age, sex, current smoker, etc.), interventions (control thera...
Cochrane's Collaboration tool was used to assess the quality of each randomized trial and the risk of bias. We analysed included trials for allocation concealment, random sequence generation, blinding of the outcome assessment, incomplete outcome data, selective reporting, blinding of the participants and personnel, and other biases.
We used RevMan 5.3 software for all statistical analyses. The degree of heterogeneity among RCTs was evaluated with the Q test and I2 statistic. I2values ≥ 50% were considered to represent significant heterogeneity, in which case a random-effects model was applied. We combined continuous data using the inverse-variance test for the risk ratio, haza...
- Huanyu Long, Hongxuan Xu, Jean-Paul Janssens, Yanfei Guo
- 2021
Conclusions: This study demonstrates that in patients with symptomatic COPD at risk of exacerbations, once-daily FF/UMEC/VI, compared with FF/VI or UMEC/VI, improves patient-perceived HRQoL and symptoms. Trial registration number: NCT02164513 .
- Maggie Tabberer, C. Elaine Jones, Sally Kilbride, David M.G. Halpin, David A. Lomas, Steven Pascoe, ...
- 2020
Feb 13, 2019 · The panel suggested three criteria, any one of which identifies a high-risk patient where escalation to triple therapy from monotherapy or double combination treatment is appropriate: 1) at least two exacerbations treated with oral corticosteroids, antibiotics, or both in the previous year; 2) at least one severe exacerbation that required hospi...
Feb 13, 2019 · While single-inhaler triple therapy (SITT) devices were not available when the Global Initiative for Chronic Obstructive Lung Disease strategy and National Institute for Health and Care Excellence guidelines were developed, two devices are now available in the UK.
